Payment overview · 2025
General Payments
$202.39
11 reported records · 8 companies
Healthcare provider profile · identity verified
Krithika Mullengada, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SUCCASUNNA, NJ · NPI 1992785562
Verified facts
What the public records show
CMS Open Payments records show Krithika Mullengada, MD received $202.39 in general payments during 2025 across 11 reported records.
GlaxoSmithKline, LLC. accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Shingrix, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.75 | 26.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.54 | 16.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.87 | 15.8% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.21 | 9.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.45 | 9.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.78 | 8.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.17 | 7.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.62 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $202.39 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.86 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.87 | 1 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 20 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 829 | 196 |
| Levothyroxine Sodium | Levothyroxine Sodium | 700 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 630 | 159 |
| Pantoprazole Sodium | Pantoprazole Sodium | 373 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 356 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 310 | 83 |
| Metformin Hcl | Metformin Hcl | 280 | 89 |
| Furosemide | Furosemide | 261 | 72 |
| Losartan Potassium | Losartan Potassium | 258 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 250 | 60 |
| Alprazolam | Alprazolam | 240 | 61 |
| Gabapentin | Gabapentin | 238 | 48 |
| Lisinopril | Lisinopril | 221 | 55 |
| Eliquis | Apixaban | 202 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 200 | 45 |
| Donepezil Hcl | Donepezil Hcl | 194 | 28 |
| Omeprazole | Omeprazole | 189 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 41 |
| Potassium Chloride | Potassium Chloride | 178 | 42 |
| Memantine Hcl | Memantine Hcl | 167 | 25 |
| Sertraline Hcl | Sertraline Hcl | 167 | 47 |
| Carvedilol | Carvedilol | 165 | 31 |
| Famotidine | Famotidine | 165 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 156 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 45 |
| Trazodone Hcl | Trazodone Hcl | 138 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 135 | 33 |
| Mirtazapine | Mirtazapine | 132 | 30 |
| Simvastatin | Simvastatin | 132 | 39 |
| Montelukast Sodium | Montelukast Sodium | 120 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 28 |
| Valsartan | Valsartan | 106 | 23 |
| Alendronate Sodium | Alendronate Sodium | 95 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 93 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 36 |
| Meloxicam | Meloxicam | 84 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 82 | 22 |
| Jardiance | Empagliflozin | 78 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 11 |
| Levetiracetam | Levetiracetam | 74 | 12 |
| Bupropion Xl | Bupropion Hcl | 69 | 22 |
| Tradjenta | Linagliptin | 66 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | suppressed |
| Ezetimibe | Ezetimibe | 64 | 20 |
| Atenolol | Atenolol | 63 | 13 |
| Divalproex Sodium | Divalproex Sodium | 63 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 20 |
| Xarelto | Rivaroxaban | 59 | 13 |
| Ozempic | Semaglutide | 58 | 19 |
| Metformin Hcl Er | Metformin Hcl | 57 | 17 |
| Pregabalin | Pregabalin | 55 | 22 |
| Nystatin | Nystatin | 53 | 25 |
| Finasteride | Finasteride | 51 | 11 |
| Spironolactone | Spironolactone | 50 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 43 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 18 |
| Latanoprost | Latanoprost | 41 | suppressed |
| Lidocaine | Lidocaine | 41 | suppressed |
| Prednisone | Prednisone | 41 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 12 |
| Methylprednisolone | Methylprednisolone | 39 | 33 |
| Torsemide | Torsemide | 38 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 33 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 16 |
| Glimepiride | Glimepiride | 35 | 14 |
| Lactulose | Lactulose | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Gemfibrozil | Gemfibrozil | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 21 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Nystop | Nystatin | 28 | 12 |
| Allopurinol | Allopurinol | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 24 |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 18 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 16 |
| Ramipril | Ramipril | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Trulicity | Dulaglutide | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Alphagan P | Brimonidine Tartrate | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Clonazepam | Clonazepam | 14 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $202.39 · 11 records | GlaxoSmithKline, LLC. | Cologuard Collection Kit, GEMTESA, MOUNJARO, NEXLETOL, Ozempic, RECORLEV, SHINGRIX, TRELEGY ELLIPTA, WELLBUTRIN, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error